That isn't quite correct. PolyMedix had limited funds, and lots of loans. They looked at the toxicity reports on Brilacidin, which were bad because they stupidly gave VERY high doses of the drug instead of starting low. (Dr. Menon realized that THAT was the problem, and that's why CTIX/IPIX used much, much lower doses so that there were only a few people who got very mild and very transient side effects -- tingling in the fingertips.)

So, PolyMedix, with its limited funds, decided to do a Hail Mary clinical trial, betting the entire company on the success or failure of ANOTHER drug, and abandoning Brilacidin.

The other drug failed, so PMX went belly-up.

That's a totally different situation than IPIX is in.